Aripra 15 Tablet

Aripra 15 Tablet is manufactured by Incepta Pharmaceuticals Limited. Aripra 15 Tablet contains 15 mg Aripiprazole. It is Atypical neuroleptic drugs class drug.

Aripra 15 (Aripra 15) is an atypical antipsychotic that has both dopamine and serotonin receptors activity. It is a partial agonist of dopamine D2 receptors that relieves the symptoms of schizophrenia. It is characterized as a dopamine system stabilizer. It is a potent partial agonist at serotonin 5-HT1A receptors and antagonist at 5-HT2A receptors. This is associated with improvement of depressive, cognitive and negative symptoms.

Uses

Schizophrenia

Schizoaffective disorder

Acute manic and mixed episodes associated with Bipolar I Disorder

Maintaining efficacy in patients with Bipolar I Disorder who are stabilized

Brand Name: Aripra 15
Generic: Aripiprazole
Weight: 15 mg
Type: Tablet
Therapeutic Class: Atypical neuroleptic drugs
Manufacturer: Incepta Pharmaceuticals Limited
Price: 9.80
Last Updated: November 21, 2020 at 6:15 pm

Dosage

Aripra 15 contains Aripiprazole 15 mg. Aripra 15 Dosage:

For Schizophrenia:

Adults-10 to 15 mg, once daily, without regard to food. Dose increment should not be made before 2 weeks, the time needed to achieve steady state.

For Bipolar mania:

Adults- 30 mg, once daily, without regard to food.

 

Side Effects

Headache, constipation, asthenia, nausea, dyspepsia, vomiting, coughing, abdominal pain.

Precaution

Aripra 15 may be associated with orthostatic hypotension (orthostatic lightheadedness).

Aripra 15 should be used with caution in patients with known cardiovascular disease (myocardial infarction or ischaemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications).

Seizures occurred in aripiprazole-treated patients. As with other antipsychotic drugs, aripiprazole should be used cautiously in patients with Alzheimer\\\'s dementia.

Aripra 15 is not approved for the treatment of patients with dementia-related psychosis.

Aripra 15

Interaction

Caution should be exercised when aripipazole is taken in combination with other centrally acting drugs and alcohol. Carbamazepine could cause an increase in aripiprazole clearance and lower blood levels. Ketoconazole, quinidine, fluoxetine or paroxetine can inhibit aripiprazole elimination and cause increased blood levels.

Pregnancy Lactation use

Aripra 15 should not be used in pregnancy as no human trial is performed. Patients should be advised not to breast-feed an infant if they are taking aripiprazole.

Contraindication

Aripra 15 is contraindicated in patients who are hypersensitive to it or to any component of this product.

Special Warning

 

Acute Overdose

Aripra 15 at doses up to 1080 mg causes no fatalities. The signs and symptoms observed with aripiprazole overdose included nausea, vomiting, asthenia, diarrhea, and somnolence.

Interaction with other Medicine

Caution should be exercised when aripipazole is taken in combination with other centrally acting drugs and alcohol. Carbamazepine could cause an increase in aripiprazole clearance and lower blood levels. Ketoconazole, quinidine, fluoxetine or paroxetine can inhibit aripiprazole elimination and cause increased blood levels.

Storage Condition